Sunday November 8 2009 | Biotechnology feed | All feeds
|
|
Prosidion Ltd
Download detailed PDF Members: (OSI) Prosidion is the diabetes and obesity business group within OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) dedicated to the discovery and development of novel drugs for the treatment of type 2 diabetes and obesity. (OSI) Prosidion's lead compound PSN9301 is a Dipeptidyl Peptidase IV (DP-IV) inhibitor currently in Phase II clinical trials. PSN357, a glycogen phosphorylase inhibitor, is undergoing Phase IIa clinical studies and PSN010, a glucokinase activator, has recently entered Phase I clinical trials. (OSI) Prosidion owns or has licensing rights to a portfolio of DP-IV medical use patents with claims covering DP-IV as a target for anti-diabetes therapy and the use of combinations of DP-IV inhibitors with other anti-diabetes drugs such as metformin. A number of non-exclusive licenses to the patent estate have been granted to major pharmaceutical companies. (OSI) Prosidion operates through OSI's wholly-owned subsidiary, Prosidion Limited, in Oxford, UK
This page has been viewed 5993 times since April 2007, the link to the organisation's website has been followed 1438 times Recent Search Terms used to find this page: prosidion licensing | Prosidion | Prosidion | prosidion ltd | Prosidion | Prosidion Limited | prosidion ltd | osi prosidion in the uk | prosidion osi GPR119 | prosidion | . Search for more companies in Oxford Search for more companies in Oxfordshire This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for Prosidion Ltd | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|